1Mitchell A J, Subramaniam H. Prognosis of depression in old age compared to middle age: a systematic review of comparative studies[J]. Am J Psychiatry,2005,162:1588-1601.
2Trivedi MH, Morris DW, Grannemann BD, et al. Symptom clusters as predictors of late response to antidepressant treatment[J] .J Clin Psychiatry,2005,66: 1064-1070.
3Rush AJ, Zimmerman M, Wisniewski SR,et al. Comorbid psychiatric disorders in depressed outpatients: dense and clinical features[J] .J Affect Disord,2005,87:43-55.
4Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine[ J]. Mol Psychiatry, 1998,3:508-511.
5Yu YW, Tsai S J, Chen TJ, et al. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders[J]. Mol Psychiatry,2002,7:1115-1119.
6Kim DK, Lira SW, Lee S, et al. Serotanin transporter gene polymorphism and antidepressant response[J]. Neuroreport, 2000, 11: 215-219.
7Murphy GM Jr, Hollander SB, Rodrigues HE, et el. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression[J]. Arch Gen Psychiatry,2004,61 : 1163-1169.
8Ito K, Yoshida K, Sato K, et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine [ J]. Psychiatry Res, 2002,111:235-239.
9Stairs KM, Stairs LJM, Schouten JSAG, et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic reviews [ J ]. Mol Psychiatry, 2004,9 : 433-441.
10Serretti A, Zanardi R, Cusin C, et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity [ J ]. Eur Neuropsychopharmacol,2001,11:375-380.
